MORRISVILLE, N.C.--(BUSINESS WIRE)--Worldwide Clinical Trials, Inc. (Worldwide), an award-winning, full-service, midsize, global contract research organization (CRO), announced today that Aman Khera joined the company’s Scientific Solutions team as global head of regulatory strategy. Khera will lead regulatory strategy and development services for the company’s sponsor clients across multiple therapeutic indications, clinical development stages and Worldwide’s expanding global clinical trial footprint.
As a regulatory affairs leader and strategist for more than 22 years, Khera will bring her expertise to projects in risk identification, mitigation and regulatory affairs at Worldwide. With new regulations, laws and innovative technology taking center stage, more sponsors — primarily small to midsize biotech innovators — require CRO partners with a sound scientific background, a global infrastructure, and experience navigating global and regional drug and device regulatory pathways. The addition of Khera will support Worldwide’s focus on staying ahead of changes in the global regulatory environment to address evolving opportunities in regulatory strategy potential roadblocks impacting timeline and financial goals.
“Khera’s proficiency and passion for drug development and regulatory intelligence will further elevate our work across research areas, such as biosimilars, rare and orphan diseases, oncology, and immunology,” said Peter Benton, president and COO, Worldwide Clinical Trials. “In addition, her commitment to revitalize and diversify the workplace environment aligns with our company’s ‘uncommon people program’ and vision to recruit, develop and retain highly skilled professionals needed to keep pace with this booming industry. We are fortunate to welcome her to our team.”
Khera joins Worldwide following a 17-year tenure with PRA Health Services, most recently serving as the head of Americas for the regulatory strategy and agency liaison team. Prior to that, Khera worked on the Orion Clinical Services and Parexel regulatory teams. Khera is an active volunteer for regulatory associations, previously serving on the editorial panel of peer-reviewed journal Regulatory Rapporteur and is currently chair of the North American chapter for The Organization for Professionals in Regulatory Affairs (TOPRA). She also serves as a member of TOPRA’s diversity committee, spearheading inclusion within industry.
“I am thrilled to join the Worldwide team – industry experts drawn from top global biopharma companies, academic institutions and key regulatory agencies,” said Khera. “Whether we are determining the best regulatory strategy for developing a drug or device in the early phases of research, ensuring a product in development is on the optimal path for regulatory approval or negotiating with regulatory agencies, Worldwide is one of the few CROs with capabilities and staffing specifically designed to help emerging and midsized biopharma sponsors successfully navigate this new global landscape, shorten time to market and position a product for commercial success.”
Khera earned her Bachelor of Science in medical biochemistry as well as a diploma in professional development from Brunel University in Middlesex, United Kingdom. She also received an award of achievement in diversity and inclusion from the University of British Columbia, Canada. In 2017, she was shortlisted for an industry-wide Regulatory Excellence award in the Inspiration category, and earlier this year, she joined the panel of distinguished professionals for the Excellence awards.
For more information on Aman Khera and the expanding Scientific Solutions and Regulatory team at Worldwide Clinical Trials, visit www.worldwide.com.
About Worldwide Clinical Trials
Worldwide Clinical Trials employs more than 1,700 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia, and Asia. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval and real-world evidence, we provide world-class, full-service drug development services.
With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, general medicine, oncology and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO.
For more information, visit http://www.worldwide.com.